PMDS — PMD Device Solutions AB Share News
0.000.00%
Last trade - 00:00- SEK13.76m
- SEK40.59m
- SEK28.62m
Brief: Promore Pharma Q3 Operating Loss Widens To SEK 8.3 Mln
Brief: Promore Pharma: Positive Phase IIb Study Results Of Ropocamptide In Venous Leg Ulcers
Brief: Promore Pharma Q2 Operating Loss Narrows To SEK 6.7 Million
Brief: Promore Pharma Appoints New CFO
Brief: Promore Pharma CFO Resigns
Brief: Promore Pharma Reached The Targeted Number Of Patients Completing Treatment
Brief: Promore Pharma Q4 Operating Loss Widens To SEK 9.4 Mln
Brief: Promore Pharma Gets About SEK 60.1 Mln From Rights Issue
Brief: Promore Pharma Q3 Operating Loss Narrows To SEK 6.7 Mln
Brief: Promore Pharma Unit Pergamum Gets Patent For PXL01 In Us
Brief: Promore Pharma Carries Out Rights Issue Of About SEK 75 Million
Brief: Promore Pharma Q2 Operating Loss Narrows To SEK 7.4 Million
Brief: Promore Pharma Granted A Patent For LL-37 In Japan
Brief: Promore Pharma Q1 Operating Loss Narrows To SEK 5.5 Mln
Brief: Promore Pharma Modifies Its Phase III Trial Of Pxl01 And Expands The Number Of Clinics In The Study
Brief: Pharmaresearch Products Use Call Option In Promore Pharma
Brief: Promore Pharma Q3 Operating Loss Widens To SEK 7.4 Million
Brief: Promore Pharma April-June Operating Profit Up At SEK 8.5 Million
Swedish stocks: seen opening higher, Ericsson off Liberum's least preferred list